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Abstract
Background and Objectives New treatments and interventions are in development to address clinical needs in heart failure. 
To support decision making on reimbursement, cost-effectiveness analyses are frequently required. A systematic literature 
review was conducted to identify and summarize heart failure utility values for use in economic evaluations.
Methods Databases were searched for articles published until June 2019 that reported health utility values for patients with 
heart failure. Publications were reviewed with specific attention to study design; reported values were categorized according 
to the health states, ‘chronic heart failure’, ‘hospitalized’, and ‘other acute heart failure’. Interquartile limits (25th percentile 
‘Q1’, 75th percentile ‘Q3’) were calculated for health states and heart failure subgroups where there were sufficient data.
Results The systematic literature review identified 161 publications based on data from 142 studies. Utility values for chronic 
heart failure were reported by 128 publications; 39 publications published values for hospitalized and three for other acute 
heart failure. There was substantial heterogeneity in the specifics of the study populations, methods of elicitation, and sum-
mary statistics, which is reflected in the wide range of utility values reported. EQ-5D was the most used instrument; the 
interquartile limit for mean EQ-5D values for chronic heart failure was 0.64–0.72.
Conclusions There is a wealth of published utility values for heart failure to support economic evaluations. Data are heter-
ogenous owing to specificities of the study population and methodology of utility value elicitation and analysis. Choice of 
value(s) to support economic models must be carefully justified to ensure a robust economic analysis.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 3-020-00984 -6) contains 
supplementary material, which is available to authorized users.
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Key Points 
This systematic literature review identifies and sum-
marizes utility values for heart failure (HF) to support 
economic evaluations, derived from 161 publications 
reporting HF utility values from 142 studies.
79.5% of the publications provided utility values on 
chronic HF, 24% on hospitalization of patients with HF, 
and 2% on other acute events (some publications pro-
vided data on multiple HF states).
EQ-5D was the most common instrument used in 73% of 
the studies based on EQ-5D values, the interquartile lim-
its (25th and 75th percentiles) of study means for chronic 
HF were 0.64 and 0.72.
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1 Introduction
Heart failure (HF) is the inability of the heart to pump suf-
ficient blood to meet the body’s needs, causing symptoms 
such as dyspnea, fatigue, and edema. It affects about 64 mil-
lion patients worldwide and carries a heavy morbidity and 
mortality burden [1, 2]. Approximately 50% of patients die 
within 5 years of diagnosis and HF is the leading cause of 
hospitalization in patients aged over 65 years [2, 3]. Heart 
failure therefore presents a large public health burden, which 
is anticipated to grow with an aging global population.
Heart failure may be chronic or acute. Chronic HF is a 
relatively stable condition. However, periods of stable heart 
function are punctuated by acute events (also referred to 
as decompensations). Chronic HF is commonly classified 
by the New York Heart Association (NYHA) classification, 
which describes the severity of symptoms and their impact 
on the patient’s physical activity and daily functioning 
[4–6]. Acute heart failure (AHF) is the rapid onset of new 
or worsening of symptoms and signs of HF, requiring urgent 
medical attention [7]. The majority of AHF cases occur in 
patients with worsening chronic HF, i.e., as a decompensa-
tion of existing disease rather than new-onset (‘de novo’) 
presentation of HF [4].
New treatments and models of care are under explo-
ration for both chronic HF with reduced left ventricular 
ejection fraction (HFrEF, LVEF < 40%) and chronic HF 
with preserved left ventricular ejection fraction (HFpEF, 
LVEF ≥ 50%). As HF has a substantial impact on health-
related quality of life (HRQoL) [6], it is important to under-
stand the effect of treatment on HRQoL and consequently 
assess cost effectiveness (CE) through a cost-utility analy-
sis, where effectiveness is measured in terms of quality-
adjusted life-years (QALYs). Health state utility values can 
be obtained via generic measures, such as the EQ-5D, or 
condition-specific measures. It is essential that a choice-
based evaluation is applied, for instance, in the shape of 
a time trade-off, to derive a utility scoring algorithm, also 
called a value set [8]. Utility values are therefore key com-
ponents that inform health technology assessment decisions. 
In methodological reviews of HF cost-effectiveness models, 
utility is one of the key drivers, and sources of heterogene-
ity, of incremental cost-effectiveness ratios, making it an 
important parameter for consideration [9, 10]. It is therefore 
essential that the values used in economic evaluations can 
be justified. The latest reporting standards from the Inter-
national Society for Pharmacoeconomics and Outcomes 
Research recommend values are obtained systematically, 
are reviewed for quality, and are consistent in the methods 
used to derive the values [11].
To the best of our knowledge, there have been no system-
atic literature reviews (SLR) of HF utility values. The aim of 
this SLR is to identify, summarize, and appraise HF utility 
values to support and inform economic evaluations.
2  Methods
2.1  Search Strategy
Sources from the National Institute for Health and Care 
Excellence, Scottish Intercollegiate Guidelines Network, 
and Canadian Agency for Drugs and Technologies in Health 
were used to develop the search strategy (Electronic Supple-
mentary Material [ESM] 1), which adhered to a prespecified 
protocol and methods recommended by the Cochrane Col-
laboration and the Centre for Reviews and Dissemination. 
MEDLINE, EMBASE, EconLit, and Centre for Reviews 
Dissemination York database (which included the National 
Health Service Economics and Evaluation Database and 
Health Technology Assessment Database) were searched for 
relevant articles published from the beginning of database 
records until June 2019. Databases were searched for pri-
mary studies that published utility values for adult patients 
(aged ≥ 18 years) with HF, regardless of treatment or inter-
vention. The search strategy allowed for the inclusion of 
studies conducted in broader patient populations if utility 
values were reported for a HF sub-population, and studies 
that reported HF utility values as valued or perceived by the 
general population and caregivers. No minimum sample size 
was set for inclusion.
Conference abstracts (ESM 1) published between 2016 
and June 2019 were searched to identify data from the gray 
literature. In addition, websites for the Canadian Agency 
for Drugs and Technologies in Health, European Medicines 
Agency, National Institute for Health and Care Excellence, 
Scottish Medicines Consortium, US Food and Drug Admin-
istration, and School of Health and Related Research Health 
Utilities Database were also reviewed. The search was also 
supplemented with relevant publications identified in a par-
allel SLR on CE models and economic evaluations in HF.
Only reports, abstracts and manuscripts published in Eng-
lish were selected for further review. References cited in 
retrieved articles were reviewed for additional publications 
that had not been already identified (citation snowballing).
As only primary studies publishing new utility values 
were of interest, CE studies, health technology assessment 
submissions, SLRs, and meta-analyses were excluded from 
the review, unless they used or published de-novo data; how-
ever, references for utility inputs cited by these publications 
were assessed for inclusion as part of the citation snowball-
ing exercise. The review was registered (Registration Num-
ber CRD42019134288) with the International Prospective 
Register of Systematic Reviews (PROSPERO) and reported 
according to the following guidelines: Preferred Reporting 
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Items for Systematic reviews and Meta-Analyses (PRISMA) 
and International Society for Pharmacoeconomics and Out-
comes Research good practices on identification, review, and 
use of health state utilities in CE models (SpRUCE) [11, 12].
2.2  Selection, Extraction, and Quality Assessment
Two reviewers independently screened database records and 
identified relevant studies for review (Fig. 1) in accordance 
with pre-defined search strategy. Data were extracted and 
primary studies with a full publication were assessed for 
quality, based on relevant criteria from the Papaioannou 
et al. [13] checklist. Data extraction and quality assessment 
were performed by one reviewer and quality checked by a 
second reviewer. Any discrepancies between the two review-
ers during selection, extraction, and quality assessment were 
adjudicated by a third reviewer.
2.3  Data Review
Publications were reviewed with specific attention to the 
design of the study that generated the utility data, the method 
of utility elicitation, the value set used to generate utility val-
ues, and the utility value summary statistic and data. There 
are two versions of the EQ-5D instrument, the original three-
level (− 3L) version and the five-level (− 5L) version that 
was introduced in 2009. All papers that were published in or 
prior to 2009 were assumed to use the EQ-5D-3L version, 
regardless of whether this was specified.
Publications were categorized according to the health 
state(s) for which utility data were reported: ‘chronic HF’, 
‘hospitalized’, and ‘other AHF’. Other AHF captured those 
publications that presented data on acute events but did 
not specify restriction to hospitalization events. Catego-
rization was based on the study population for which the 
utility values were elicited. In instances where the utility 
value publication did not report sufficient detail around the 
study population, where feasible, further information on the 
study was sourced from either clinicaltrials.gov or the study 
Fig. 1  Preferred Reporting 
Items for Systematic reviews 
and Meta-Analyses (PRISMA) 
flow chart displaying the num-
ber of publications included as 
well as the number of publica-
tions that were excluded, with 
reasons. CE cost effectiveness, 
HF, heart failure, SLR system-
atic literature review
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publication. Publications were assigned the category ‘HF’ 
where there was insufficient information to assign it to a 
more specific health state.
The interquartile limits (IQLs) of study means (25th 
percentile ‘Q1’, 75th percentile ‘Q3’) were calculated for 
HF subgroups where there were sufficient data. For inclu-
sion in the IQLs, calculation studies had to have a sample 
size ≥ 100. Weighted averages were calculated where pub-
lications reported utility values for two or more study arms 
and baseline data used where utility values were reported 
for multiple timepoints. Baseline data were used so as to not 
confound the analysis with the effect of different therapies, 
which adds further heterogeneity. Publications that reported 
utility values for individual NYHA classes were omitted 
from the calculation if it was not possible to calculate an 
overall utility value as a weighted average of the classes’ 
values, as there is often an unequal distribution of patients 
across the NYHA classes, only a weighted average would 
avoid bias [14, 15]. Follow-up studies were also omitted. In 
occasional cases where publications reported utility values 
for multiple value sets, values based on the most frequently 
reported value set for the UK were used to calculate Q1 and 
Q3.
3  Results
3.1  Study Identification and Description
The SLR identified 161 primary publications that reported 
utility value data (including disutilities) for HF, based on 
elicitation from 142 studies (Fig. 1, PRISMA flow diagram, 
Table 1, ESM 2). There was considerable heterogeneity in 
the design of studies; 78 were observational studies, 43 ran-
domized controlled trials, and 13 cost-utility studies. Stud-
ies differed in terms of sample size (range 6–28,500) and 
treatment arms. Furthermore, substantial diversity was seen 
within study populations. Some studies (28.5%) recruited 
a broad population of patients with HF (e.g., patients with 
chronic HF), others (7%) recruited hypothetical patients with 
HF or the general population, while the majority (64.5%) 
had much more specific inclusion criteria based on HF type, 
severity, or comorbidity (e.g., patients in specific NYHA 
classes and below pre-specified LVEF thresholds). There 
was also heterogeneity in how utility values were reported 
(Table 1). The mean was the most reported statistic (n = 87), 
eight publications reported both mean and median, and five 
reported the median. Other reported data included variabil-
ity statistics, coefficients, estimates, weights, and base-case/
model inputs; 35 studies did not state the statistic for the 
reported data.
Table 1  Overview of studies (n = 142) and publications (n = 161) identified in the systematic literature review
AHF acute heart failure, CHF chronic heart failure, HF heart failure, HRQoL health-related quality of life, HUI Health Utilities Index, NR not 
reported, NS not specified,  RCT randomized controlled trial, SF Short Form
a Exceeds 142, some studies (16) used multiple elicitation instruments, from which utility values were calculated
b Includes HUI, HUI-2, HUI-3, SF-6D, SF-12, SF-36, and Quality of Well-Being Index
c Exceeds 161, as some studies published data on multiple HF populations/value sets/parameters
Design Country of study HRQoL elicitation  instrumenta
Description of elicitation studies (n = 142)
 RCT 43 Multinational 22 EQ-5D (NS) 37
 Non-randomized interventional 5 US 28 EQ-5D-3L 62
 Observational 78 UK 17 EQ-5D-5L 5
 Cost-utility model 13 Spain 11 Vignette 18
 Meta-analysis 1 Other 46 Otherb 21
 NR/unclear 2 NR 18 NR 8
Health  statec Value  setc Summary  statisticc
Description of utility value publications (n = 161)
 CHF 128 UK 33 Mean 95
 Hospitalization 39 US 13 Median 13
 Other AHF 3 Spain 5 Estimates/inputs 10
 HF (Not specified) 10 Australian 3 Coefficient 8
Other 12 Other 11
Literature 14 NR 35
NR 88
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Publications were categorized according to the health 
state for which utility data were reported. Although new-
onset cases of ‘de novo’ acute HF do occur, the disease 
course of HF is typically that of a chronic condition, with 
hospitalization episodes due to a worsening of the previ-
ously stable condition [4]. This is reflected in the literature 
with 128 publications focusing on chronic HF, 39 on hos-
pitalization, and only 3 on other AHF (Table 1). The health 
state could not be defined for ten publications. Of note, some 
publications reported utility values for several HF health 
states. EQ-5D (3L and 5L) was the most common elicita-
tion instrument, being used in 104 studies. Value sets used 
also varied between studies. The UK value set was the most 
frequently reported value set (n = 33); however, the majority 
of publications (n = 89) did not report the value set used.
Most studies (n = 130) recruited patients with HF, of 
which 113 elicited data using patient-reported outcomes. 
One study used proxy report by caregivers (both informal 
and healthcare providers) [16]; six studies recruited a gen-
eral population and one study used healthcare providers, 
and elicited utility values for vignettes describing specific 
health states [17–23]; and five cost-utility models defined 
hypothetical HF populations deriving utility values from the 
literature [24–28].
Full manuscripts (n = 91) included in the review were 
assessed for quality according to relevant criteria from the 
Papaioannou et al. checklist (ESM 3). In general, publica-
tions were of good quality in reporting response rates, using 
population characteristics that matched those modeled (e.g., 
chronic HF, hospitalization), using generic preference-based 
instruments, and assessing utility values elicited directly 
from patients. However, loss to follow-up and missing data 
were not reported or addressed by many of the papers.
This high level of heterogeneity between publications 
limits the ability to compare and synthesize studies. Con-
sequently, focus was predominantly placed on those papers 
that used the EQ-5D instrument and published mean health 
utility values as the summary statistic.
3.2  Utility Values in Patients with Chronic HF
The SLR identified 52 studies that published mean utility 
values for patients with chronic HF, using the EQ-5D (− 3L 
or − 5L) instrument, of which 35 (Table 2) met inclusion 
criteria for calculating Q1 and Q3 limits of 0.64–0.72. In a 
subgroup analysis of those publications that used the EQ-
5D-3L instrument (n = 22), the IQL did not substantially 
change (0.64–0.71). Only two publications that met crite-
ria for inclusion in the IQL calculation used the EQ-5D-5L 
instrument. Squire et al. reported a mean utility value of 
0.60 for patients with HF with NYHA II–IV who had been 
diagnosed for at least 12 months [29]. Zhu et al. reported a 
mean utility value of 0.73 for a broad population of patients 
with chronic HF [30]. Eleven of the 35 papers were excluded 
from − 3L and 5L subgroup analyses because the EQ-5D 
version could not be determined.
The chronic HF populations of studies included in the 
IQL calculations were varied ranging, for example, from 
advanced HF populations (with or waiting for heart trans-
plant), to more general chronic HF populations who were 
stable for at least 3 months [31, 32]. A review of data by 
NYHA class clearly illustrates the impact of the severity of 
chronic HF on utility values. The SLR identified 11 pub-
lications that provided data on mean EQ-5D utility values 
according to NYHA class, of which nine were included in 
the IQL calculation; one study was omitted from the IQL 
calculation as it grouped NYHA classes (I/II and III/IV), and 
a second study was omitted because it published the mean 
difference in utility values between classes [33, 34]. Aside 
from Zhu et al. [30], which reported lower utility values for 
NYHA I vs NYHA class II, increasing NYHA class was 
associated with lower utility values (Fig. 2). Interquartile 
limits were 0.79–0.86 for NYHA class I, 0.75–0.81 for class 
II, 0.61–0.69 for class III, and 0.51–0.66 for class IV.
The impact of a value set on the utility value is illustrated 
in two publications. Berg et al. calculated mean utility values 
for a large population of Swedish patients with chronic HF, 
using Swedish and UK value sets [35]. Baseline mean utility 
score calculated using the UK value set was 0.696; whereas 
the utility value was nearly 20% higher when calculated with 
the Swedish value set (0.828) [35]. Eurich et al. calculated 
mean utility values for patients with HFrEF managed in an 
outpatient setting using US and UK value sets that gave 
mean scores of 0.74 and 0.66, respectively [36].
Of those papers included in the IQL calculation, nine 
publications published utility values for patients with 
HFrEF, giving an IQL of 0.67–0.74. None of the publica-
tions eligible for inclusion in the IQL calculation focused on 
patients with HFpEF; however, two publications that were 
not eligible compared utility values in HFrEF and HFpEF. 
Berg et al., which used the EQ-5D-3L instrument but did 
not specify the summary statistic, reported a lower utility in 
HFpEF (0.65) than in HFrEF (0.72–0.73) [37]. Nafees et al., 
which used a vignette elicitation method, reported similar 
values between HFrEF and HFpEF populations [21].
In addition to understanding utility values for HF popu-
lations, understanding disutility due to chronic HF in the 
general population (or other patient populations) may be of 
value for modeling studies. The SLR identified ten papers, 
regardless of the elicitation instrument or statistic reported, 
that provided data on the disutility of chronic HF (ESM 4). 
The large degree of heterogeneity between study designs, 
in particular, the background population, instrument used, 
and statistic reported, prevents a detailed collective review 
of these studies. However, in most cases, the presence of HF 








Table 2  Mean EQ-5D (3L or 5L) utility values for patients with chronic heart failure (CHF)




Study population HF sample size (N) HRQoL instrument Population value set Utility values for CHF 
mean (measure of 
variability)a
Andreae 2018 [65] Observational Sweden Outpatients with HF, 





EQ-5D-3L NR No depression: 0.79 
(SD 0.20)
Depression: 0.62 (SD 
0.20)
Austin 2005 [66] RCT UK Patients with CHF, 
NYHA class 





EQ-5D-3L NR Standard care: 0.65 
(95% CI 0.61–0.70)
Experimental care: 0.67 
(95% CI 0.62–0.72)
Berg 2015 [35] Observational (SHFR) Sweden Patients with CHF 5334 EQ-5D-3L Swedish and UK Swedish value set: 
0.828 (SD 0.135)
UK value set: 0.696 
(SD 0.302)
Calvert 2005 [56] RCT (CARE-HF) Multinational Patients with HF with 
left ventricular sys-
tolic dysfunction and 
cardiac dysynchrony
740 EQ-5D-3L UK 0.60 (95% CI 0.58–
0.62)





Spain Patients with CHF 
with LVEF < 40%
400 EQ-5D NR 0.74 (NR 0.22)
Comin-Colet 2013 
[57]
RCT (FAIR-HF) Multinationalb Patients with CHF Placebo: 153
Experimental: 298
EQ-5D-3L NR Placebo: 0.69 (SE 0.01)
Experimental: 0.68 (SE 
0.01)
De Rivas 2008 [32] Observational (INCA 
study)
Spain Patients with CHF, 
stable for at least 
3 months
2161 EQ-5D-3L Spanish 0.63 (95% CI 0.62–
0.64)
Delgado 2014 [60] Observational 
(INOESCARO 
study)
Spain Patients with CHF 369 EQ-5D NR 0.7553 (SD 0.2739)
Emin 2016 [31] Observational 
(UKCTA study)
UK Patients with 
advanced HF
Assessed for HTx: 
194
Listed for




EQ-5D NR Assessed for HTx: 0.50 
(SD 0.30)
Listed for HTx on medi-
cal therapy: 0.44 (SD 
0.27)
LVAD: 0.58 (SD 0.26)
Patients after HTx: 0.74 
(SD 0.27)
Eurich 2006 [36] Observational Canada and USA Patients with HF with 
LVEF < 0.40% in an 
outpatient setting
298 EQ-5D-3L USA and
UK
UK: 0.66 (SD 0.26)











Table 2  (continued)




Study population HF sample size (N) HRQoL instrument Population value set Utility values for CHF 
mean (measure of 
variability)a





























EQ-5D-3L NR Standard care: 0.6651
Experimental care 
0.7080
Iqbal 2010 [71] Observational UK Patients with CHF
with left ventricular 
systolic dysfunction 
on echocardiography
179 EQ-5D-3L NR 0.57 (SEM 0.03)
Jolly 2009 [72] RCT (BRUM-CHF) UK Patients with HF with 
LVEF ≤ 40% and 










Observational Greece Patients with CHF 
who were admitted 
for elective cardiac 
surgery (scheduled 
or emergency)
251 EQ-5D-3L UK 0.703 (SD 0.303)
Kraai 2013 [74] Observational The Netherlands Patients with HF, 
NYHA I–IV
100 EQ-5D-3L UK 0.68 (SD 0.26)
Kularatna 2017 [61] RCT Australia Patients with CHF 
with moderate-to-
severe symptoms 
of HF, NYHA class 
II–III
280 EQ-5D-3L Australian 0.71
Li 2013 [75] RCT (HF-ACTION) Multinationalb Patients with HF, 
NYHA II–IV with 
LVEF ≤ 35%
2288 EQ-5D US 0.808 (SD 0.141)
Luo 2011 [76] Observational USA Patients with conges-
tive HF








Table 2  (continued)




Study population HF sample size (N) HRQoL instrument Population value set Utility values for CHF 
mean (measure of 
variability)a
Marti 2010 [64] Observational Spain Patients with HF, 
NYHA II–IV
NYHA class II: 297
NYHA class III/IV: 
153
EQ-5D-3L NR NYHA Class II: 0.8407 
(NR 0.1887)
NYHA Class III/IV: 
0.6624 (NR 0.2848)
Marti 2011 [59] Observational Spain Patients with HF, 
NYHA II–IV
NYHA class II: 272
NYHA class III/IV: 58
EQ-5D NR NYHA Class II: 0.8058 
(0.2048)
NYHA Class III/IV: 
0.6135 (0.3032)
Patel 2012 [77] Observational NR Patients with HF, 
NYHA III/IV, 
LVEF ≤ 30%
140 EQ-5D NR 0.67 (0.19)
Peters 2014 [78] Observational UK Patients with HF 137 EQ-5D UK 0.64 (95% CI 0.59–
0.69)
Pisa 2015 [79] Observational Germany Patients with HF with 








Spertus 2005 [80] Observational Canada, USA Outpatients with HF 
with LVEF < 0.40
476 EQ-5D-3L UK Baseline: 0.67 (SD 
0.26)
Squire 2017 [29] Observational 
(ASSESS)
UK Patients with HF with 
NYHA II–IV, diag-
nosed for at least 
12 months
185 EQ-5D-5L UK 0.60 (SD 0.25)
Sullivan 2006 [81] Observational USA Subpopulation of 
patients with CHF
284 EQ-5D-3L USA 0.636
Trueman 2017 [34] RCT (PARADIGM-
HF)
NR Patients with HF with 
reduced ejection 
fraction
NYHA class I: 384
NYHA class II: 5829
NYHA class III: 1987
NYHA class IV: 59
EQ-5D-3L NR NYHA class I/II: 0.814
NYHA class III/IV: 
0.676
Viriato 2017 [82] Observational Multinational Patients with CHF 2398 EQ-5D NR 0.71 (NR 0.29)





EQ-5D-3L NR Standard care: 0.58
Experimental care: 0.59








Usual care: 0.737 (SD 
0.234)
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statistical significance was not assessed or demonstrated for 
all disutility values).
3.3  Utility Values in Hospitalized Patients with HF
Acute HF events, whether new-onset (‘de novo’) events or, 
more commonly, acute decompensations of chronic HF, usu-
ally lead to urgent hospital admission [7]. The SLR identi-
fied 31 publications that reported EQ-5D utility values for 
hospitalization, of which two were based on the ACEND-HF 
trial and four on the WHICH study. Patients with HF are at 
risk of all-cause hospitalization as well as hospitalization 
for HF [2]. Twenty of the 31 EQ-5D publications focused 
on hospitalization for HF, three on all-cause hospitalization, 
and eight failed to clearly report the cause of hospitalization.
Many of the studies did not report, or poorly defined, 
the timing of HRQoL elicitation during the hospitaliza-
tion event. Understanding when HRQoL questionnaires 
are administered is important as two studies suggest that 
utility values change rapidly during a hospitalization event. 
Ambrosy et al. published EQ-5D-3L utility values for the 
ASCEND-HF trial, which investigated the effect of nesir-
itide in patients hospitalized with AHF. Mean utility value, 
for the total study population (regardless of treatment arm) 
increased rapidly from 0.56 at baseline (assumed near to 
time of admission) to 0.67 at 24 h of hospitalization; by the 
time the patient was discharged (day 10), the utility value 
had further increased to 0.79 [38]. A second smaller study by 
Swinburn et al. reported mean utility values of patients with 
HF, as perceived by caregivers and healthcare profession-
als, following admission to hospital. EQ-5D-3L values, as 
perceived by experienced cardiac nurses (n = 50), increased 
from 0.199 on day 1 post-hospital admission to 0.563 on 
day 3 [16]. By day 7, utility values had increased to 0.817.
For the IQL calculation, papers that published mean 
EQ-5D utility values (for patients with HF) were included 
regardless of the cause of hospitalization, if they reported 
inpatient or discharge utility values. Four papers were iden-
tified that provided utility values collected during hospital 
admission, and six at discharge (Table 3), yielding IQLs of 
0.54–0.63 and 0.64–0.73, respectively. Differences in study 
design, including whether the study focused on all-cause 
hospitalization or hospitalization for HF, are likely to have 
contributed to the variability in estimates. In addition, when 
the EQ-5D questionnaire was administered during hospital 
stay is also likely to have contributed to the variation in 
utility values.
Four papers provided longer term, follow-up, mean 
EQ-5D utility values on patients hospitalized for HF (ESM 
5) [38–41]. Temporal changes in utility values follow-
ing discharge vary between studies and follow-up care. In 
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Ten publications reported EQ-5D disutility values for a 
hospitalization event, with four using data from the SHIFT 
study (Table 4). While a large degree of study heterogeneity 
(in particular, the summary statistic reported) prevents IQL 
from being calculated, it is evident that a hospitalization 
event reduces utility (Table 4). The publications based on 
the SHIFT study provide several interesting insights. Two 
publications by Griffiths et al., both of which use EQ-5D 
data from the SHIFT study, indicate that disutility because 
of hospitalization increases with NYHA class; differences 
in the reported values between the publications suggest sen-
sitivity to differences in the analyses applied in the differ-
ent publications (both papers report the results of a mixed 
model using NYHA classes as a time-varying covariate but 
the model building strategies appear to be different with an 
automatic backward elimination used to retain covariates in 
the latter paper) [42, 43]. Kansal et al. provide disutilities 
specifically for HF hospitalizations based on SHIFT data; 
disutilities for one or two HF hospitalizations are similar 
(parameter estimates [standard error] − 0.076 [0.007] and 
− 0.074 [0.013]), but increases for patients with three or 
more HF hospitalizations (− 0.133 [0.016]) [44]. Apart from 
McMurray et al. [45], none of the papers that publish hospi-
talization disutility values provide time boundaries around 
the data, i.e., when the decrement is applied and how long 
the effect lasts. According to McMurray et al., disutility is 
− 0.105 for patients hospitalized in the previous 30 days and 
reduces to − 0.054 for patients hospitalized in the previous 
30–90 days (UK value set) [45]. This suggests that disutility 
because of hospitalization reduces over time, which is con-
sistent with other studies publishing trends in utility values 
following discharge (ESM 5).
3.4  Utility Values in Patients with Other AHF Events
Acute HF events do not always result in hospitalization. 
Three studies reported utility values for a broader group of 
patients with AHF, none of which used EQ-5D. Collins et al. 
is a modeling study [46], while Davies et al. and Matza et al. 
use vignette methodology and surveyed general populations 
[17, 20].
4  Discussion
This SLR identified a wealth of HF utility data, with 161 
publications reporting data from 142 studies. This large 
evidence base provides opportunities for the relevant util-
ity values to be identified and used in cost-utility analy-
ses. However, opportunities to compare and synthesize the 
Fig. 2  Mean utility scores for chronic heart failure, based on EQ-5D 
health-related quality-of-life data, according to New York Heart 
Association (NYHA) class [30, 57–64]. Black circle: Comin-Colet 
2013, white circle: Delgardo 2014, black square: Gohler 2009, white 
square: Grustam 2018, white up-pointing trianlge: Kularatna 2017, 
white up-pointing trianlge: Marti 2010, black diamond: Marti 2011, 
white diamond: Yao 2007, grey diamond: Zhu 2017
Review of Utility Values in Heart Failure
studies were limited, as heterogeneity between the studies 
was considerable. This degree of heterogeneity is not unique 
to HF, a review of CE analyses in cardiovascular disease by 
Ara et al. found utilities values varied hugely in terms of 
the patient population and the methods (in particular, the 
instruments and value set) used to obtain them, resulting in 
considerable heterogeneity in the data [47].
From the quality assessment, reporting of loss to follow-
up and missing data in HF utility publications needs to be 
improved to enable the reader to establish whether bias 
might have been introduced [48]. However, as this review 
focused on baseline data, lack of reporting loss to follow-up 
did not pose a risk of bias in this instance. Furthermore, the 
specifics of the instrument (e.g., EQ-5D-3L vs EQ-5D-5L) 
and country value set applied should also be reported 
routinely.
In this SLR, EQ-5D was the dominant instrument 
accounting for 73% of utility studies. While other instru-
ments may be relevant for specific uses, for the purpose 
of a comparative synthesis, heterogeneity was reduced by 
focusing the detailed review on those studies that used the 
EQ-5D instrument. Furthermore, as utility values are sen-
sitive to study specificities, such as study population and 
value set used (as well as instrument for elicitation), IQLs 
Table 3  Mean EQ-5D (3-level or 5-level) utility values during hospitalization and at discharge
AHF acute heart failure, CBI clinic-based intervention program, CHF chronic heart failure, CI confidence interval, HRQoL health-related quality 
of life, HBI home-based intervention program, HF heart failure, NR not reported, NYHA New York Heart Association, RCT randomized con-
trolled trial, SD standard deviation, SE standard error
a Based on information given in clinicaltrials.gov or primary study publication
b Baseline (admission): study also reports 24 h
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Table 4  Disutility because of a hospitalization event, EQ-5D (3-level or 5-level) values








Disutility value due 
to hospitalization 
event
Bertoldi 2013 [24] Cost-utility model Brazil Hypothetical HF 
population
NR Literature Base case (estimate 
range): − 0.100 (− 
0.050 to − 0.200)
Briggs 2017 [92] RCT (SAVOR-
TIMI 53)
Multinationala Subgroup of 
patients with 
T2DM with HF 
complications
373 UK Coefficient (SE): − 
0.065 (0.014)
Griffiths 2014 [42] RCT (SHIFT) Multinationala Patients with CHF 5313 UK Disutility value
NYHA class I: − 
0.04
NYHA class II: − 
0.07
NYHA class III: − 
0.10
NYHA class IV: − 
0.29
Griffiths 2017 [43] RCT (SHIFT) Multinationala Patients with CHF 5313 UK Weights loss hospi-
talization
NYHA I: − 0.07
NYHA II: − 0.03
NYHA III: − 0.08
NYHA IV: − 0.21
Kansal 2016 [44] RCT (SHIFT) Multinationala Patients with CHF NR NR Estimate (SE) for:
1 HF hospitaliza-
tion: − 0.076 
(0.007)
2 HF hospitaliza-
tions: − 0.074 
(0.013)
≥3 HF hospitaliza-




RCT (SHIFT) Multinationala Patients with CHF 4199 (with 









For not experiencing 




For 3 or more HF-
related hospitaliza-
tion: − 0.133
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were calculated for the comparative synthesis, as utilities 
for a broad population cannot be accurately represented by 
a single value.
The IQL for chronic HF was 0.64–0.72, with a trend of 
decreasing utility with increasing disease severity observed 
(IQLs 0.79–0.86 for NYHA class I, 0.75–0.81 for class 
Table 4  (continued)








Disutility value due 
to hospitalization 
event










UK and USA Disutility for 
hospital stay for 




who died: US 
value set: − 0.05 
(− 0.08 to − 0.01)
UK value set: − 




US value set: − 0.10 
(− 0.14 to − 0.06)
UK value set: − 
0.11 (− 0.15 to 
− 0.06)
Maru 2017 [91] RCT (WHICH) Australia Hospitalized 
patients with 
a diagnosis of 
CHF
NR NR Disutility for each 
additional all-
cause readmission 
mean (95% CI): − 






Multinationala Patients with 
chronic HFrEF




UK: − 0.105 (− 
0.116 to − 0.094)
Denmark − 0.081 






UK: − 0.054 (− 
0.116 to − 0.094)
Denmark: − 0.044 
(− 0.090 to − 
0.072)










CHF chronic heart failure, CI confidence interval, HF heart failure, HFrEF heart failure reduced ejection fraction, MI myocardial infarction, NR 
not reported, NYHA New York Heart Association, RCT randomized controlled trial, SD standard deviation, SE standard error
a Based on information given in clinicaltrials.gov
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II, 0.61–0.69 for class III and 0.51–0.66 for class IV). As 
expected, utilities were lower for hospitalized patients with 
HF (compared with chronic HF), with an IQL of 0.54–0.63. 
However, IQLs at discharge (0.64–0.73) were near identi-
cal to those reported for the general chronic HF population.
Hospitalization of patients with HF is an area of focus for 
this review as a treatment goal of HF is to prevent hospital 
admission. Consequently, ‘hospitalization for heart failure’ 
is a key outcome in many HF trials [7, 49]. Understanding 
the impact of hospitalization on utility is likely to be cen-
tral to economic evaluations of new treatments. While 39 
publications reported utility data following hospitalization 
of patients with HF, there were limitations in the data. In 
particular, the timing of administration of the EQ-5D ques-
tionnaire was poorly defined and some publications failed 
to report the cause of hospitalization, e.g., HF specific, car-
diovascular, or all-cause. Longitudinal studies of HF utility 
were rare; only four studies reported utilities during hospi-
talization (admission or discharge) as well as at follow-up 
timepoints, none provided pre-admission data. Furthermore, 
studies reporting disutility because of hospitalization did 
not, in general, specify when disutility was assessed during 
hospitalization or time-bound the effect of a hospitalization 
event. Consequently, despite the large number of publica-
tions, there are important limitations to the hospitalization 
data that need careful consideration when applying these 
values in economic models.
Acute HF events may not always result in hospitalization 
but may require urgent medical attention and treatment; a 
recent HF trial included ‘urgent HF visit’ alongside hospital-
ization for HF and cardiovascular death in the primary com-
posite endpoint [50]. However only three studies reported 
utility values for a broader group of patients with acute HF, 
none of which used EQ-5D. Consequently, utility data of 
acute heart failure, not restricted to hospitalization, are lim-
ited, highlighting it as an area for further investigation.
To the best of our knowledge, this is the first dedicated 
SLR of utility in HF. Dyer et al. reviewed EQ-5D utility 
values in a broad group of cardiovascular diseases [51]. 
They identified 150 studies that published EQ-5D values 
for chronic HF, with mean values ranging from 0.31 to 0.78 
[51]. The IQLs for mean EQ-5D values for chronic HF cal-
culated in this review fall within the range published by Dyer 
et al. This comprehensive SLR expands on Dyer et al. While 
mainly focusing on EQ-5D (because of its high usage), this 
review is not restricted to this instrument and captures an 
additional 9 years of the latest data. Furthermore, utility val-
ues for specific health states (specifically chronic HF and 
hospitalization) are analyzed.
Rankin et  al. reviewed trial-based economic evalua-
tions of HF interventions that derive QALYs as an outcome 
measure, to identify approaches used to measure and value 
change in HRQoL [52]. They identified 20 studies reporting 
economic evaluations based on 18 individual trials, with 
most studies (n = 17) using generic preference-based meas-
ures to describe HRQoL and derive QALYs, commonly the 
EQ-5D-3L. Rankin et al. did not provide the utility values 
reported per study but rather they examined whether the 
evaluations undertaken alongside trials identified significant 
changes in QALYs. Our review expands on Rankin et al. to 
identify, summarize, and appraise primary studies publish-
ing HF utility values, regardless of the treatment or interven-
tion and study design provided the studies report on de-novo 
utility data.
4.1  Limitations
Whilst we were inclusive in our approach to selecting stud-
ies, this review might be affected by publication bias which, 
although beyond the control of a systematic review, could 
have distorted our summaries with an over-representation 
of studies with larger and/or statistically significant results. 
Further, language bias is also possible, as only publications 
in English were included in the review.
Because of the fact that HF is asymptomatic in its first 
stages, early assessment of the severity of HF is a crucial 
task [53]. The most commonly employed classifications for 
HF severity are NYHA and American College of Cardiol-
ogy/American Heart Association stages of HF. The NYHA 
classification system has been criticized because of the fact 
that it is based on a subjective evaluation and thus intra-
observer variability can be introduced [54]. Although we 
do acknowledge the criticism on the NHYA classification 
system, we did investigate how NYHA class impacted utility 
as this was the most frequently reported classification for HF 
severity; while none of the identified studies provided utili-
ties stratified per American College of Cardiology/American 
Heart Association stages of HF.
Acute HF events, whether ‘de novo’ events or, more com-
monly, acute decompensations of chronic HF, usually lead 
to urgent hospital admission. In this review, acute HF was 
driven by hospitalization except from three studies (listed 
under ‘other AHF events’). The differentiation between ‘de 
novo’ and ‘acute-on-chronic’ HF cases would have some 
merit because the initial hospitalization with diagnosis of 
HF is generally considered more costly. However, we did not 
differentiate among the two types of acute events because of 
studies that either do not clearly define the population with 
HF hospitalization or they include both patients with chronic 
HF and newly diagnosed HF in the sample of patients admit-
ted to hospital [40, 41, 55]. To avoid grouping the studies 
based on the reviewers’ interpretation of the data, we did 
present the findings according to the health state for which 
utility data were reported: ‘chronic HF’, ‘hospitalized’, and 
‘other AHF’. Consequently, all studies reporting utilities for 
HF hospitalization were grouped together regardless of ‘de 
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novo’ or ‘acute-on-chronic’ events. It is possible that many 
chronic HF studies may have investigated patients with an 
exacerbation of chronic HF (‘acute-on-chronic’) and there-
fore the study population may not be per se stable chronic 
patients. The manner in which we approached the studies of 
patients with chronic HF is that when the study reported util-
ity for an acute event (e.g., hospitalization) clearly defined 
by the authors, we grouped the study under ‘hospitalized 
HF’ or ‘other AHF’.
Although age of respondents was reported in most of 
the studies, direct comparison of outcomes based on age 
between studies was not possible owing to the large differ-
ences in the set-up of the studies. Looking at within-study 
reporting of the role of age, some insights have been offered 
only by the studies by Calvert et al. and McMurray et al. 
[45, 56]. The former reported utilities for patients with 
HF stratified by age, and revealed that the impact of HF 
on quality of life appears to be independent of age with no 
specific trend identified (25–34 years: 0.55; 35–44 years: 
0.65; 45–54 years: 0.60; 55–64 years: 0.60; 65–74 years: 
0.60; 75 + years: 0.60). McMurray et al., in the supplemental 
results, reported the results of multivariable mixed models 
for utilities, but for both cohorts (UK and Colombian, Dan-
ish analysis) the centered-on-the-mean coefficient for age 
was very small (− 0.001) and borderline statistically signifi-
cant (95% confidence interval − 0.001, 0.000), indicating a 
weak disutility effect by older ages.
5  Conclusions
There is a wealth of published utility values providing a 
useful source for health economic modelers. In line with lat-
est International Society for Pharmacoeconomics and Out-
comes Research recommendations, utility values should be 
obtained systematically, reviewed for quality, and derived 
using consistent methods [11]. This SLR provides evidence 
on suitable values to support future economic evaluations in 
HF and, where feasible, summarizes the data; utility value 
IQLs for chronic HF were 0.64–0.72. We advocate the use 
of systematic reviews to inform the parameters of the mod-
els used for cost-effectiveness analyses because utilities are 
among the key drivers of the models used in HF [10]. This 
study is an exhaustive repository of data from which utility 
values can be selected, justified (relevant to specific mod-
eling scenarios), and used. Meanwhile, for those modelers 
using de novo utility values, data identified in this SLR pro-
vide a useful resource for benchmarking.
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